NCT05169567 2026-01-16postMONARCHEli Lilly and CompanyPhase 3 Active not recruiting368 enrolled 14 charts
NCT04975308 2025-07-11EMBER-3Eli Lilly and CompanyPhase 3 Active not recruiting874 enrolled 29 charts 1 FDA
NCT06253195 2025-06-05BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsBeiGenePhase 1 Active not recruiting33 enrolled